Spectral Medical Inc
TSX:EDT

Watchlist Manager
Spectral Medical Inc Logo
Spectral Medical Inc
TSX:EDT
Watchlist
Price: 0.495 CAD 2.06% Market Closed
Market Cap: 140m CAD
Have any thoughts about
Spectral Medical Inc?
Write Note

Operating Margin
Spectral Medical Inc

-700.8%
Current
-575%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-700.8%
=
Operating Profit
-14.1m
/
Revenue
2m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
CA
Spectral Medical Inc
TSX:EDT
140m CAD
-701%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
316.5B USD
28%
US
Amgen Inc
NASDAQ:AMGN
141.2B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.3B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
135.7B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.2B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-22%
Country CA
Market Cap 140m CAD
Operating Margin
-701%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 316.5B USD
Operating Margin
28%
Country US
Market Cap 141.2B USD
Operating Margin
19%
Country US
Market Cap 117.1B USD
Operating Margin
38%
Country US
Market Cap 105.3B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 135.7B AUD
Operating Margin
26%
Country US
Market Cap 78.2B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 36B EUR
Operating Margin
-22%
No Stocks Found

Spectral Medical Inc
Glance View

Market Cap
140m CAD
Industry
Biotechnology

Spectral Medical, Inc. engages in the development and commercialization of therapeutic treatment for septic shock. The company is headquartered in Toronto, Ontario and currently employs 31 full-time employees. The firm has conducted a Phase III clinical trial for its lead product, PMX (Toraymyxin PMX-20R), which is for the treatment of patients with septic shock and endotoxemia that is measured by the Company’s Endotoxin Activity Assay (EAA). EAA and PMX are both Health Canada licensed and commercially available in Canada. The firm through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new set of platforms addressing renal replacement therapy (RRT) across the dialysis spectrum. SAMI is targeting the acute RRT market, while DIMI is targeting the chronic RRT market.

EDT Intrinsic Value
0.038 CAD
Overvaluation 92%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-700.8%
=
Operating Profit
-14.1m
/
Revenue
2m
What is the Operating Margin of Spectral Medical Inc?

Based on Spectral Medical Inc's most recent financial statements, the company has Operating Margin of -700.8%.